NCT07787949 Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects
| NCT ID | NCT07787949 |
| Status | Recruiting |
| Phase | — |
| Sponsor | October 6 University |
| Condition | Injectable Platelet-Rich Fibrin |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-03-11 |
| Primary Completion | 2027-03-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-03-11 with a primary completion date of 2027-03-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the clinical and radiographic effectiveness of injectable platelet-rich fibrin (i-PRF) combined with minimally invasive non-surgical therapy (MINST) versus MINST alone in the management of class II furcation defects.
Eligibility Criteria
Inclusion Criteria: * Patients of both genders \>18 years old, medically free of systemic diseases affecting periodontal regeneration. * Diagnosis of stage III, grade B periodontitis (according to the AAP/EFP classification 2018) with the presence of class II furcation defect in either the maxillary (buccal) or mandibular arch (buccal or lingual) as determined by clinical evaluation and confirmed by radiographic evaluation. * Gingival margin and interdental bone positioned coronally to the furcation entrance. * Commitment to maintenance visits and follow-up. * Absence of primary endodontic lesions. Exclusion Criteria: * Patients suffering from any systemic diseases that may affect the outcome of periodontal therapy, including diabetes, immune deficiencies, etc; * Patients that received periodontal surgical treatments in the past 12 months. * Smoking (current or in past 5 years) * Prolonged treatment with antibiotics or anti-inflammatory agents within 6 months prior to periodontal therapy. * Pregnant and lactating females. * Teeth with hopeless prognosis * Third molars
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07787949 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Injectable Platelet-Rich Fibrin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07787949 currently recruiting?
Yes, NCT07787949 is actively recruiting participants. Contact the research team at 23110295.pg@o6u.edu.eg for enrollment information.
Where is the NCT07787949 trial being conducted?
This trial is being conducted at Giza, Egypt.
Who is sponsoring the NCT07787949 clinical trial?
NCT07787949 is sponsored by October 6 University. The trial plans to enroll 30 participants.